Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment mod…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.51 | $-0.34 |
| Estimado | $-0.50 | $-0.48 | $-0.44 | $-0.48 |
| Sorpresa | — | — | -15.9% | +29.2% |
| Métrica | IMTX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | -40.6% | -39.2% | -1.4% |
| ROA | -34.9% | -30.9% | -4.0% |
| Current Ratio | 11.72 | 2.73 | +8.99 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -34.9% | — |
| ✗Flujo de caja operativo positivo | −€177M | −€158M |
| ✗Rentabilidad sobre activos al alza | -34.9% | 2.2% |
| ✓Caja operativa/activos supera al ROA | -31.4% | ROA -34.9% |
| –Menos deuda a largo plazo | — | — |
| ✓Mejor liquidez (ratio corriente) | 11.72 | 9.26 |
| ✗Sin aumentar el nº de acciones | 122M | 107M |
| –Margen bruto al alza | — | — |
| –Rotación de activos al alza | — | — |
| Calidad del negocio | FY25 |
|---|---|
| ✗ROCE > 10 % | -35.0% |
Immatics N.V. cotiza a 6.73 USD y tiene una capitalización bursátil de $1.0B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud